{"id":"CHEMBL1023","canonicalSmiles":"C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C","inchiKey":"NAVMQTYZDKMPEU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"BEXAROTENE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bexarotene","Targretin","Targretine"],"synonyms":["Bexarotene","LG-100069","LG100069","LGD-1069","LGD1069"],"crossReferences":{"DailyMed":["bexarotene"],"PubChem":["124893633","144206219","144212724","170465308","50125754"],"Wikipedia":["Bexarotene"],"drugbank":["DB00307"],"chEBI":["50859"]},"count":21,"approvedIndications":["EFO_0000616","EFO_0002913"],"linkedTargets":{"rows":["ENSG00000204231","ENSG00000143171","ENSG00000186350"],"count":3},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","MONDO_0002108","EFO_0000249","EFO_0002913","MONDO_0007254","EFO_0000222","EFO_1000100","EFO_1001110","EFO_1000747","EFO_0000305","EFO_0003060","EFO_0000565","EFO_0003032","EFO_0004192","MONDO_0008903","EFO_0000574","EFO_0000676","EFO_1001051","EFO_0001378","EFO_0000432","MONDO_0020077","EFO_1000785","EFO_0000692","EFO_0005411"],"count":25},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for cutaneous t-cell lymphoma and neoplasm and has 19 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1078534","canonicalSmiles":"C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12","inchiKey":"LUJVUUWNAPIQQI-QAGGRKNESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANDROSTENEDONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["93576728"],"drugbank":["DB07373"],"chEBI":["40799"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1095282","canonicalSmiles":"CN(C)C(=O)OC1N=C(c2ccccc2)c2cc(Cl)ccc2N(C)C1=O","inchiKey":"PXBVEXGRHZFEOF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CAMAZEPAM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Camazepam"],"crossReferences":{"Wikipedia":["Camazepam"],"drugbank":["DB01489"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL110094","canonicalSmiles":"CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21","inchiKey":"GWWLWDURRGNSRS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MELITRACEN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Melitracen"],"crossReferences":{"PubChem":["50125798"],"Wikipedia":["Melitracen"],"drugbank":["DB13384"]},"childChemblIds":["CHEMBL2107109"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL113142","canonicalSmiles":"Nc1nc(NCCc2ccc(O)cc2)nc2nc(-c3ccco3)nn12","inchiKey":"PWTBZOIUWZOPFT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZM-241385","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ZM-241385"],"crossReferences":{"PubChem":["11113871","26752042"],"drugbank":["DB08770"]},"childChemblIds":["CHEMBL1628684"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1160945","canonicalSmiles":"O=C(O)[C@H](O)[C@H](O)COP(=O)(O)O","inchiKey":"ZCZXOHUILRHRQJ-PWNYCUMCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1160945","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03108"],"chEBI":["49003"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1164318","canonicalSmiles":"NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O.O=S(=O)(O)O","inchiKey":"HIBICIOPDUTNRR-XTHCGPPUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMIKACIN SULFATE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL177","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Amiglyde","Amikacin Sulfate","Amikin"],"synonyms":[],"crossReferences":{"PubChem":["8139947"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1184499","canonicalSmiles":"Cc1cc(C)[n+](CCc2ccc(S(N)(=O)=O)cc2)c(C)c1","inchiKey":"UXBCHTZINZNVRG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1184499","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04763"]},"childChemblIds":["CHEMBL352535"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1200386","canonicalSmiles":"CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C","inchiKey":"FNPXMHRZILFCKX-KAJVQRHHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PREDNICARBATE","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dermatop","Dermatop e emollient","Prednicarbate"],"synonyms":["HOE 777","HOE-777","LAS-189961","LAS-41003 COMPONENT PREDNICARBATE","LAS189961","Prednicarbate","S 77 0777","S-77 0777","S-77-0777","S-770777"],"crossReferences":{"DailyMed":["prednicarbate"],"PubChem":["144204238","56463553"],"Wikipedia":["Prednicarbate"],"drugbank":["DB01130"]},"count":4,"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["HP_0000964","EFO_0000676","EFO_0007512","MONDO_0002026"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 investigational indications."}
{"id":"CHEMBL1200511","canonicalSmiles":"CC(=O)O.CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O","inchiKey":"NGCGMRBZPXEPOZ-HBBGHHHDSA-N","drugType":"Protein","blackBoxWarning":false,"name":"GONADORELIN ACETATE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1007","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cystorelin","Factrel","GnRH","Gonadotropin Releasing Hormone","Lh Releasing Factor","Lutrelef","Lutrepulse","Lutrepulse kit"],"synonyms":["ABBOTT-41070","Gonadorelin acetate","Gonadorelin acetate mixture","Gonadorelin diacetate","Luteinizing hormone-releasing factor diacetate tetrahydrate"],"count":8,"linkedTargets":{"rows":["ENSG00000109163"],"count":1},"linkedDiseases":{"rows":["MONDO_0002146","EFO_0000545","EFO_0000731","EFO_0000673","MONDO_0007254","Orphanet_478","MONDO_0008315","MONDO_0018555","EFO_0001663"],"count":9},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 8 investigational indications."}
{"id":"CHEMBL1200592","canonicalSmiles":"CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C","inchiKey":"VVOIQBFMTVCINR-WWMZEODYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DESOXYCORTICOSTERONE PIVALATE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Percorten"],"synonyms":["Desoxycorticosterone pivalate","Desoxycorticosterone trimethylacetate"],"crossReferences":{"PubChem":["144205152"],"drugbank":["DB01134"],"chEBI":["50782"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1200805","canonicalSmiles":"COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.O=C(O)CC(O)C(=O)O","inchiKey":"IUSFTUWHKCSCDY-BHDTVMLSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DILTIAZEM MALATE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL23","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tiamate"],"synonyms":["Diltiazem malate","MK-793"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996."}
{"id":"CHEMBL1200964","canonicalSmiles":"CN(C)CCC=C1c2ccccc2CCc2ccccc21.Cl","inchiKey":"KFYRPLNVJVHZGT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"AMITRIPTYLINE HYDROCHLORIDE","yearOfFirstApproval":1961,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL629","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Amitid","Amitril","Amitriptyline hydrochloride","Cytriptyline","Domical","Elavil","Endep","Lentizol","Limbitrol 5","Saroten","Saroten retard","Triptafen","Triptafen-m","Tryptizol","Tryptizol-75"],"synonyms":["Amitriptyline hydrochloride","NIH 10794","NSC-104210"],"crossReferences":{"DailyMed":["amitriptyline%20hydrochloride"],"PubChem":["144206673","144208476","144213917","170464758","17389180","26747443","26751626","49816669","50105841","855970"]},"count":3,"approvedIndications":["EFO_0003761"],"linkedTargets":{"rows":["ENSG00000108576","ENSG00000103546"],"count":2},"linkedDiseases":{"rows":["HP_0000989","EFO_0003761","EFO_0009387"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for unipolar depression and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201108","canonicalSmiles":"Cc1nc2c([nH]1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1-2.Cl","inchiKey":"BTYHAFSDANBVMJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CONIVAPTAN HYDROCHLORIDE","yearOfFirstApproval":2005,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1755","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vaprisol"],"synonyms":["CI-1025","Conivaptan hydrochloride","YM-087","YM087"],"crossReferences":{"chEBI":["31430"]},"count":2,"linkedTargets":{"rows":["ENSG00000126895","ENSG00000166148"],"count":2},"linkedDiseases":{"rows":["HP_0002902","EFO_0001421"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 2 investigational indications."}
{"id":"CHEMBL1201127","canonicalSmiles":"CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1.CCO","inchiKey":"QWSHKNICRJHQCY-VBTXLZOXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DARUNAVIR ETHANOLATE","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1323","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Prezista"],"synonyms":["Darunavir Ethanolate","Darunavir ethanolate"],"count":2,"approvedIndications":["EFO_0000544","EFO_0000764"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for infection and hiv infection."}
{"id":"CHEMBL1201136","drugType":"Small molecule","blackBoxWarning":false,"name":"TITANIUM DIOXIDE","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dundee","E45 sun","Reflectant"],"synonyms":["CI-(1975)NO.77891","E 171","E-171","E171","INS NO.171","INS-171","NSC-15204","NSC-200C","Titanium dioxide","Titanium peroxide"],"crossReferences":{"PubChem":["124898737"],"Wikipedia":["Titanium_dioxide"],"chEBI":["32234"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 2 investigational indications."}
{"id":"CHEMBL1201193","canonicalSmiles":"CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C","inchiKey":"LEBVLXFERQHONN-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVOBUPIVACAINE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Bupivacaine (-)-form","Levobupivacaine"],"crossReferences":{"PubChem":["11112642","29215441"],"Wikipedia":["Levobupivacaine"],"drugbank":["DB01002"],"chEBI":["6149"]},"childChemblIds":["CHEMBL1200749"],"count":7,"linkedTargets":{"rows":["ENSG00000007314"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0005323","EFO_1000631","MONDO_0007254","EFO_0009085","HP_0000175","EFO_0000284","HP_0003418","EFO_0009387","EFO_0003843","EFO_0000537","EFO_0002950","EFO_0003964","HP_0100543","EFO_0002506","EFO_0003766","EFO_1002012","EFO_0003833","EFO_0009676","EFO_0000668","HP_0000023","HP_0001822","EFO_1001792","EFO_0005251"],"count":24},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 7 investigational indications."}
{"id":"CHEMBL1201487","drugType":"Enzyme","blackBoxWarning":false,"name":"SACROSIDASE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Sucraid"],"synonyms":["Sacrosidase"],"crossReferences":{"DailyMed":["sacrosidase"],"DrugCentral":["5043"],"Wikipedia":["Sacrosidase"]},"description":"Enzyme drug with a maximum clinical trial phase of IV that was first approved in 1998."}
{"id":"CHEMBL1201534","drugType":"Unknown","blackBoxWarning":false,"name":"DANAPAROID SODIUM","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Orgaran"],"synonyms":["Danaparoid","Danaparoid sodium","ORG 10172","ORG-10172"],"count":2,"approvedIndications":["HP_0004419"],"linkedTargets":{"rows":["ENSG00000117601"],"count":1},"linkedDiseases":{"rows":["HP_0004419","HP_0001873"],"count":2},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for recurrent thrombophlebitis and has 1 investigational indication."}
{"id":"CHEMBL1201535","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENYLPROPANOLAMINE POLISTIREX","yearOfFirstApproval":1984,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL61006","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Neurotoxicity"],"year":2002},"tradeNames":[],"synonyms":["Phenylpropanolamine polistirex"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. It was withdrawn in United States  in 2002 due to Neurotoxicity."}
{"id":"CHEMBL1201656","drugType":"Protein","blackBoxWarning":false,"name":"INSULIN SUSP ISOPHANE PURIFIED PORK","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Insulin insulatard nph nordisk","Nph iletin ii (pork)","Nph purified pork isophane insulin"],"synonyms":["Insulin susp isophane purified pork"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1979."}
{"id":"CHEMBL1201765","canonicalSmiles":"CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1.O=C(O)/C=C/C(=O)O","inchiKey":"MWHXMIASLKXGBU-RNCYCKTQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FESOTERODINE FUMARATE","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201764","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fesoterodine fumarate","Toviaz"],"synonyms":["Fesoterodine fumarate","SPM 8272","SPM 907","SPM-8272","SPM-907"],"crossReferences":{"DailyMed":["fesoterodine%20fumarate"]},"count":2,"approvedIndications":["EFO_1000781"],"linkedTargets":{"rows":["ENSG00000133019","ENSG00000181072"],"count":2},"linkedDiseases":{"rows":["HP_0000020","EFO_1000781"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for overactive bladder and has 1 investigational indication."}
{"id":"CHEMBL1201835","drugType":"Antibody","blackBoxWarning":false,"name":"USTEKINUMAB","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Stelara","Stelera"],"synonyms":["CNTO 1275","CNTO-1275","TT-20","Ustekinumab","Ustekinumab "],"crossReferences":{"DailyMed":["ustekinumab"],"DrugCentral":["4966"],"Wikipedia":["Ustekinumab"]},"count":22,"approvedIndications":["EFO_0000676","EFO_0003778","EFO_0000540"],"linkedTargets":{"rows":["ENSG00000113302"],"count":1},"linkedDiseases":{"rows":["Orphanet_797","MONDO_0013730","EFO_0000729","EFO_0000685","EFO_1000710","EFO_0003780","MONDO_0019269","EFO_0003898","EFO_0003778","EFO_0000274","EFO_0000540","EFO_1001486","EFO_0000384","MONDO_0044881","EFO_0007187","EFO_1001209","EFO_0003885","Orphanet_247353","EFO_1001231","EFO_0002690","EFO_0000398","EFO_0001359","EFO_0000676","Orphanet_99842","EFO_0003921","EFO_0003872"],"count":26},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 19 investigational indications."}
{"id":"CHEMBL1204165","canonicalSmiles":"C[C@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1.Cl","inchiKey":"WQVZLXWQESQGIF-WJKBNZMCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DILEVALOL HYDROCHLORIDE","yearOfFirstApproval":1990,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL27193","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"],"classes":["Hepatotoxicity"],"year":1990},"tradeNames":[],"synonyms":["Dilevalol hydrochloride","SCH 19927"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990. It was withdrawn in United Kingdom  in 1990 due to Hepatotoxicity."}
{"id":"CHEMBL1229517","canonicalSmiles":"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F","inchiKey":"GPXBXXGIAQBQNI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VEMURAFENIB","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Zelboraf"],"synonyms":["PLX-4032","PLX4032","RG 7204","RG-7204","RO 5185426","RO-51-85426","RO-5185426","Vemurafenib"],"crossReferences":{"DailyMed":["vemurafenib"],"Wikipedia":["Vemurafenib"],"drugbank":["DB08881"],"chEBI":["63637"]},"count":16,"approvedIndications":["EFO_0000616","EFO_0000756","EFO_0000389","EFO_0002617","EFO_0000311"],"linkedTargets":{"rows":["ENSG00000157764"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000365","MONDO_0002108","EFO_0000756","EFO_1000209","EFO_0000222","EFO_0003060","EFO_0000311","EFO_1001951","EFO_1000489","EFO_1000318","EFO_1001480","EFO_1000956","EFO_0000389","EFO_0000326","EFO_0000574","EFO_0001378","MONDO_0024880","EFO_0002617"],"count":19},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 11 investigational indications."}
{"id":"CHEMBL1229908","canonicalSmiles":"CCN(CC)C(=O)c1ccc(O)c(OC)c1","inchiKey":"BQJODPIMMWWMFC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHAMIVAN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Clairvan","Vandid"],"synonyms":["Etamivan","Ethamivan"],"crossReferences":{"PubChem":["11111131","144203686","144203687","170466295","50104185","56422402","85231028","855940","90340666"],"drugbank":["DB08989"]},"count":1,"approvedIndications":["EFO_0000684"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for respiratory system disease."}
{"id":"CHEMBL1232399","canonicalSmiles":"COC(=O)C1CCN(C(=O)c2ccc(NCc3cnc4nc(N)nc(N)c4n3)cc2)CC1","inchiKey":"NYNAFINLHQEHKU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232399","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07689"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232731","canonicalSmiles":"NC(C(=O)O)C(=O)O","inchiKey":"JINBYESILADKFW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232731","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02289"],"chEBI":["17475"]},"childChemblIds":["CHEMBL3360545"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234965","canonicalSmiles":"CCCCCCCCCC(=O)CC(=O)N[C@H]1CCNC1=O","inchiKey":"VEYZCVBECUYIJZ-AWEZNQCLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1234965","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08323"],"chEBI":["44612"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236802","canonicalSmiles":"[Xe]","inchiKey":"FHNFHKCVQCLJFQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"XENON","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Xenon"],"crossReferences":{"drugbank":["DB13453"],"chEBI":["49957"]},"childChemblIds":["CHEMBL1200673","CHEMBL1200685","CHEMBL4594411"],"count":11,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 11 investigational indications."}
{"id":"CHEMBL1237070","canonicalSmiles":"CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)[O-])c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1.[Na+]","inchiKey":"KOOAFHGJVIVFMZ-WZPXRXMFSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"MICAFUNGIN SODIUM","yearOfFirstApproval":2005,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL457547","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fungard","Mycamine"],"synonyms":["FK-463","FK463","Micafungin sodium","Micafungin sodium salt"],"crossReferences":{"DailyMed":["micafungin%20sodium"],"chEBI":["80105"]},"count":4,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 4 investigational indications."}
{"id":"CHEMBL1255840","canonicalSmiles":"CC1(C)CCC(NC(=O)[C@@H](N)CCC(=O)O)CC1","inchiKey":"VCRGLZYPNNAVRP-JTQLQIEISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NEBOGLAMINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cr2249","Neboglamine","XY-2401"],"crossReferences":{"PubChem":["144204806","50106666","90341776"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL1305","canonicalSmiles":"c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1","inchiKey":"REYFJDPCWQRWAA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANTAZOLINE","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Antaz sulf","Vasocon-a"],"synonyms":["Antazoline","Vasocon-A"],"crossReferences":{"PubChem":["11112519","11113348","124882433","50100471","50100472"],"Wikipedia":["Antazoline"],"drugbank":["DB08799"],"chEBI":["84115"]},"childChemblIds":["CHEMBL1256819","CHEMBL1200550"],"count":2,"approvedIndications":["HP_0001742","EFO_0003785"],"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["MP_0001845","EFO_0000678","EFO_0000275","HP_0001742","EFO_0003785"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for nasal obstruction and allergy."}
{"id":"CHEMBL131890","canonicalSmiles":"Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(O)(O)=S)[C@@H](O)[C@H]1O","inchiKey":"NLTUCYMLOPLUHL-KQYNXXCUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ATPGAMMAS","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ATP-gammaS","Atpgammas"],"crossReferences":{"drugbank":["DB02930"],"chEBI":["27575"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL133097","canonicalSmiles":"COC(=O)N[C@]1(C(N)=O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O","inchiKey":"ZQTAMPRAONLFQI-FMTWGGRWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL133097","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04013"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1332971","canonicalSmiles":"Cc1c(Cl)cccc1Nc1ncccc1C(=O)O","inchiKey":"CLOMYZFHNHFSIQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLONIXIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Clonixin","SCH 10304"],"crossReferences":{"PubChem":["144205329","29216065","50086862"],"drugbank":["DB09218"],"chEBI":["76200"]},"childChemblIds":["CHEMBL4303711","CHEMBL1729342"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1335656","canonicalSmiles":"CC(=O)N=c1sc(S(N)(=O)=O)nn1C","inchiKey":"FLOSMHQXBMRNHR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1335656","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144204015"],"drugbank":["DB00703"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1339216","canonicalSmiles":"O=C(Oc1ccccc1)c1ccccc1O","inchiKey":"ZQBAKBUEJOMQEX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENYL SALICYLATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phenyl Salicylate","Phenyl salicylate","Salol"],"crossReferences":{"PubChem":["144207008","144209009","144213266","170465501","17389589","26753033"],"Wikipedia":["Phenyl_salicylate"],"drugbank":["DB11071"],"chEBI":["34918"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL136145","canonicalSmiles":"C[N+](C)(C)CCS","inchiKey":"VFUGTBZQGUVGEX-UHFFFAOYSA-O","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL136145","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01803"]},"childChemblIds":["CHEMBL147699"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1370","canonicalSmiles":"CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1","inchiKey":"VOVIALXJUBGFJZ-KWVAZRHASA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"BUDESONIDE","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aircort","Budeflam aquanase","Budelin novolizer","Budenofalk","Budesonide","Cortiment","Duoresp spiromax","Entocort","Entocort cr","Entocort ec","Ortikos","Preferid","Pulmaxan","Pulmicort","Pulmicort flexhaler","Pulmicort l.s.","Pulmicort respules","Rhinocort","Rhinocort allergy","Rhinocort aqua","Rhinocort aqua 64","Symbicort","Uceris"],"synonyms":["Budesonide","MAP-0010","MAP0010","R01AD05","S-1320"],"crossReferences":{"DailyMed":["budesonide"],"PubChem":["56422168","855541","90341081"],"Wikipedia":["Budesonide"],"drugbank":["DB01222"],"chEBI":["3207"]},"count":42,"approvedIndications":["EFO_0005854","EFO_0000729","HP_0006536","EFO_0000270","EFO_0000464","EFO_0006505","EFO_0000341","HP_0001742","EFO_0000384","EFO_0003956"],"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0007486","EFO_0007183","EFO_0000756","EFO_0000464","EFO_0010638","EFO_0009657","MONDO_0007254","EFO_1000637","EFO_0003882","EFO_1001486","EFO_1001293","HP_0004798","HP_0002043","EFO_0005676","Orphanet_70589","EFO_1001223","EFO_1001295","MONDO_0008903","Orphanet_786","EFO_1001417","HP_0025267","EFO_0005628","EFO_0005854","MONDO_0013730","EFO_0008521","EFO_0008572","HP_0002014","EFO_0008590","EFO_1001294","EFO_0009661","EFO_0007140","EFO_1000782","EFO_0004194","EFO_1002029","EFO_0000384","EFO_0004599","HP_0001742","HP_0002110","EFO_0004232","HP_0006536","EFO_0004268","MONDO_0100096","EFO_0000684","EFO_1000391","EFO_0000270","EFO_0006505","EFO_1001411","EFO_0000341","HP_0025428","EFO_0003918","EFO_0003956","EFO_0003785"],"count":53},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 10 approved and 32 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1378","canonicalSmiles":"CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2","inchiKey":"XCTYLCDETUVOIP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"THIETHYLPERAZINE","yearOfFirstApproval":1961,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Thiethylperazine","Torecan"],"crossReferences":{"Wikipedia":["Thiethylperazine"],"drugbank":["DB00372"],"chEBI":["9544"]},"childChemblIds":["CHEMBL2359670","CHEMBL3989478","CHEMBL1326247","CHEMBL1201074","CHEMBL1200856"],"count":3,"approvedIndications":["EFO_0003785"],"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["EFO_0000249","EFO_0003785"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for allergy and has 2 investigational indications."}
{"id":"CHEMBL13828","canonicalSmiles":"O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1","inchiKey":"BAINIUMDFURPJM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXATOMIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tinset"],"synonyms":["Oxatomide","R 35,443","R-35443"],"crossReferences":{"PubChem":["11111579","144203770","170466059","50100302","50106789","50106790","85231171","855791"],"Wikipedia":["Oxatomide"],"drugbank":["DB12877"]},"count":2,"approvedIndications":["EFO_0003785"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for allergy and has 1 investigational indication."}
{"id":"CHEMBL139423","canonicalSmiles":"O=C(O)C(=O)Nc1sc2c(c1C(=O)O)CCSC2","inchiKey":"ZPDVRWNOCOREGF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL139423","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02072"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1413176","canonicalSmiles":"Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C","inchiKey":"BRZANEXCSZCZCI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NIFENAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nifenazone"],"crossReferences":{"PubChem":["11112511","144204070","170466050","26666234","26748748"],"drugbank":["DB13407"]},"count":4,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1449490","canonicalSmiles":"Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1.O=C(O)/C=C\\C(=O)O","inchiKey":"AEIUZSKXSWGSRU-QXGDPHCHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1449490","maximumClinicalTrialPhase":0,"parentId":"CHEMBL490","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["26719776","49648462","49681640"],"chEBI":["64194"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1487310","canonicalSmiles":"Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O.Cl.O","inchiKey":"WRZJOBREMUDSSV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1487310","maximumClinicalTrialPhase":0,"parentId":"CHEMBL46","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["50085471"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL152452","canonicalSmiles":"CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(C(=O)O)O[C@H]1[C@@H](O)[C@@H](O)CO","inchiKey":"SQVRNKJHWKZAKO-USOVHJGOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SIALIC ACID","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aceneuramic acid","N-acetylneuraminic acid","NSC-111756","Sialic acid","Sialic acids n-acetylneuraminic acid","UX-001","UX001"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1530581","canonicalSmiles":"c1ccc2sc(SN3CCOCC3)nc2c1","inchiKey":"MHKLKWCYGIBEQF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1530581","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144204527","170465568","3717542","50105063"],"drugbank":["DB14202"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1534","canonicalSmiles":"Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C","inchiKey":"AUNGANRZJHBGPY-SCRDCRAPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIBOFLAVIN","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["E-b2","Flavaxin","Freeda","Riboflavine","Vitamin B 2","Vitamin G"],"synonyms":["E101","INS NO. 101(I)","Lactoflavin","NCI-0033298","NSC-33298","Riboflavin","Riboflavin (vit b2)","Riboflavin tetrabutyrate","Vitamin b2","Vitamin g"],"crossReferences":{"PubChem":["144204364","144205267","144208831","144213297","170465063","17389635"],"drugbank":["DB00140"],"chEBI":["17015"]},"count":18,"approvedIndications":["EFO_0003966","EFO_0003884","EFO_0004272","EFO_0001070","HP_0001891"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 5 approved and 13 investigational indications."}
{"id":"CHEMBL1567328","canonicalSmiles":"COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Mg+2]","inchiKey":"KWORUUGOSLYAGD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OMEPRAZOLE MAGNESIUM","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1503","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Omeprazole magnesium","Prilosec","Prilosec otc"],"synonyms":["H 168/68 MAGNESIUM","Omeprazole magnesium","Omeprazole magnesium salt"],"crossReferences":{"DailyMed":["omeprazole%20magnesium"],"PubChem":["49665950","49681830"]},"count":1,"linkedTargets":{"rows":["ENSG00000105675"],"count":1},"linkedDiseases":{"rows":["EFO_0003948"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003 and has 1 investigational indication."}
{"id":"CHEMBL1572050","canonicalSmiles":"CCCCCCCCCCC(CO)CCCCCCCC","inchiKey":"LEACJMVNYZDSKR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OCTYLDODECANOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Octyldodecanol"],"crossReferences":{"PubChem":["144212611","170465533","29217971"],"drugbank":["DB14134"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1604","canonicalSmiles":"CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1","inchiKey":"RDLPVSKMFDYCOR-UEKVPHQBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEPHRADINE","yearOfFirstApproval":1974,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Anspor","Cefradine","Cephradine","Ecosporina","Nicef","Velosef","Velosef '125'","Velosef '250'","Velosef '500'"],"synonyms":["Cefradine","Cephradine","SK&F D-39304","SK-D-39304","SQ 11436","SQ 22022 [DIHYDRATE]","SQ-11436","SQ-22022"],"crossReferences":{"PubChem":["144207037","170465355"],"Wikipedia":["Cefradine"],"drugbank":["DB01333"],"chEBI":["3547"]},"childChemblIds":["CHEMBL4303427"],"count":1,"approvedIndications":["EFO_0000771"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and is indicated for bacterial disease."}
{"id":"CHEMBL1614641","canonicalSmiles":"C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1","inchiKey":"ARPYQKTVRGFPIS-VIFPVBQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUNOXAPROFEN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Flunoxaprofen"],"crossReferences":{"Wikipedia":["Flunoxaprofen"],"drugbank":["DB13317"],"chEBI":["76154"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1616","canonicalSmiles":"CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3.Cl","inchiKey":"SKYZYDSNJIOXRL-BTQNPOSSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"APOMORPHINE HYDROCHLORIDE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL53","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Apo-go","Apo-go pen","Apo-go pfs","Apokyn","Apomorph hcl","Britaject","Bromophin","Dacepton","Diagesil","Diamorph hcl","Diamorph roche","Diamorph,cocaine,chlorpromazine","Diaphine","Euphorin","Kynmobi","Uprima"],"synonyms":["Apomorphine HCl","Apomorphine hydrochloride","Apomorphine hydrochloride hemihydrate","Apomorphine hydrochloride hydrate","Diamorphine hydrochloride ","NSC-11442"],"crossReferences":{"DailyMed":["apomorphine%20hydrochloride"]},"count":3,"approvedIndications":["EFO_0002508"],"linkedTargets":{"rows":["ENSG00000149295","ENSG00000069696","ENSG00000151577"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","EFO_0002508","EFO_0003882"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for parkinson's disease and has 2 investigational indications."}
{"id":"CHEMBL1679","canonicalSmiles":"Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O","inchiKey":"VVIAGPKUTFNRDU-ABLWVSNPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEUCOVORIN","yearOfFirstApproval":1952,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Leucovorin"],"crossReferences":{"DailyMed":["leucovorin%20calcium"],"Wikipedia":["Folinic_acid"],"drugbank":["DB00650"],"chEBI":["15640"]},"childChemblIds":["CHEMBL3184463","CHEMBL3707260","CHEMBL1201138"],"count":17,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 17 investigational indications."}
{"id":"CHEMBL1697712","canonicalSmiles":"Cl.O=C(O)CCCCCCNC1c2ccccc2CCc2ccccc21","inchiKey":"VDPUXONTAVMIKZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMINEPTINE HYDROCHLORIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL418995","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Amineptine"],"crossReferences":{"chEBI":["50003"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1721515","canonicalSmiles":"O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1","inchiKey":"WDLRUFUQRNWCPK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TETRAXETAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DOT-A","DOTA","NSC-681107","Tetraxetan"],"crossReferences":{"PubChem":["518671","56320897"],"chEBI":["61028"]},"count":3,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1722209","canonicalSmiles":"Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O","inchiKey":"TWHNMSJGYKMTRB-VEIFNGETSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TOLTERODINE TARTRATE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1382","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Detrol","Detrol la","Tolterodine tartrate"],"synonyms":["PNU-200583E","Tolterodine l-tartrate","Tolterodine tartrate"],"crossReferences":{"DailyMed":["tolterodine%20tartrate"],"PubChem":["49681822"]},"count":1,"approvedIndications":["EFO_1000781"],"linkedTargets":{"rows":["ENSG00000133019","ENSG00000181072"],"count":2},"linkedDiseases":{"rows":["EFO_0006865","EFO_1000781"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998 and is indicated for overactive bladder."}
{"id":"CHEMBL1725880","canonicalSmiles":"CCOc1cc(OCC)c(C(=O)CCC(=O)O)cc1OCC","inchiKey":"YPTFHLJNWSJXKG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TREPIBUTONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Trepibutone"],"crossReferences":{"PubChem":["144206005","170465772","50112702"],"drugbank":["DB13311"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1734","canonicalSmiles":"O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1","inchiKey":"FBOUYBDGKBSUES-VXKWHMMOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SOLIFENACIN","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vesicare"],"synonyms":["Solifenacin"],"crossReferences":{"DailyMed":["solifenacin%20succinate"],"PubChem":["50113280"],"Wikipedia":["Solifenacin"],"drugbank":["DB01591"]},"childChemblIds":["CHEMBL1200803","CHEMBL2361425"],"count":5,"approvedIndications":["HP_0000020","HP_0000103"],"linkedTargets":{"rows":["ENSG00000133019","ENSG00000181072"],"count":2},"linkedDiseases":{"rows":["HP_0000103","EFO_0003103","EFO_0006865","HP_0000020","HP_0001268","EFO_1000781","EFO_0000284","EFO_0004710","HP_0011277"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for urinary incontinence and polyuria and has 3 investigational indications."}
{"id":"CHEMBL187460","canonicalSmiles":"C[C@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C","inchiKey":"GVKKJJOMQCNPGB-JTQLQIEISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CRYPTOTANSHINONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cryptotanshinone"],"crossReferences":{"PubChem":["24824127","26757029","521176"],"drugbank":["DB15579"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1892201","canonicalSmiles":"CCCCC1C(=O)NN(c2ccccc2)C1=O","inchiKey":"REOJLIXKJWXUGB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MOFEBUTAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mofebutazone","Monophenylbutazone"],"crossReferences":{"PubChem":["89855698"],"drugbank":["DB13629"],"chEBI":["76252"]},"count":3,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1897150","canonicalSmiles":"Cl.NCC(CC(=O)O)c1ccc(Cl)cc1","inchiKey":"WMNUVYYLMCMHLU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1897150","maximumClinicalTrialPhase":0,"parentId":"CHEMBL701","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["858232"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL190044","canonicalSmiles":"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C","inchiKey":"LORDFXWUHHSAQU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIMEBUTINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Trimebutine","Trimebutine maleate"],"crossReferences":{"Wikipedia":["Trimebutine"],"drugbank":["DB09089"]},"childChemblIds":["CHEMBL1325297"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1908335","canonicalSmiles":"CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O","inchiKey":"XXXSJQLZVNKRKX-YQRDHHIGSA-N","drugType":"Protein","blackBoxWarning":false,"name":"DEPREOTIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Depreotide","P829"],"crossReferences":{"drugbank":["DB11628"]},"description":"Protein drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1996652","canonicalSmiles":"CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1","inchiKey":"HDAMOICMOAXFLJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHYLBENACTYZIUM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["50125792"],"drugbank":["DB13181"]},"childChemblIds":["CHEMBL2106570"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2022968","canonicalSmiles":"CN1CCN(Cc2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N(C)C)n3)cc2)CC1","inchiKey":"YUAALFPUEOYPNX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DUBERMATINIB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dubermatinib","HCl-2084","TP-0903","TP0903","Tp 0903","Tp-0903"],"crossReferences":{"drugbank":["DB15187"]},"childChemblIds":["CHEMBL4594281"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2029605","canonicalSmiles":"CC(C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC1=O","inchiKey":"JXPWLIYXIWGWSA-CLBRJLNISA-N","drugType":"Protein","blackBoxWarning":false,"name":"LIVOLETIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZP 531","AZP-531","Azp-531","Livoletide"],"crossReferences":{"drugbank":["DB15188"]},"count":2,"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL203125","canonicalSmiles":"O=CN(O)CCCP(=O)(O)O","inchiKey":"GJXWDTUCERCKIX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FOSMIDOMYCIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fosmidomycin"],"crossReferences":{"PubChem":["174006643"],"Wikipedia":["Fosmidomycin"],"drugbank":["DB02948"],"chEBI":["443725"]},"childChemblIds":["CHEMBL2164257"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL205821","canonicalSmiles":"CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)CF","inchiKey":"SUUHZYLYARUNIA-YEWWUXTCSA-N","drugType":"Protein","blackBoxWarning":false,"name":"CHEMBL205821","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07744"]},"description":"Protein drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2074972","canonicalSmiles":"COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1","inchiKey":"QZVNQOLPLYWLHQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BENIDIPINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Benidipine","Benidipine hydrochloride"],"count":1,"linkedTargets":{"rows":["ENSG00000157388","ENSG00000081248","ENSG00000102001","ENSG00000151067"],"count":4},"linkedDiseases":{"rows":["EFO_0003884","EFO_0000319"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2103737","drugType":"Small molecule","blackBoxWarning":false,"name":"HYDROXOCOBALAMIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alpharedisol","Cobalin-h","Cyanokit","Hepavit","Hydroxocobalamin","Hydroxomin","Megamilbedoce","Neo-cytamen"],"synonyms":["Hydroxocobalamin","Hydroxocobalamin acetate","Hydroxocobemine"],"crossReferences":{"DailyMed":["hydroxocobalamin"],"DrugCentral":["4309","4644"],"chEBI":["27786"]},"count":4,"approvedIndications":["EFO_0004272","EFO_0003894"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for acne and anemia (phenotype) and has 2 investigational indications."}
{"id":"CHEMBL2103764","canonicalSmiles":"CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)c1csc(N)n1","inchiKey":"MQLRYUCJDNBWMV-GHXIOONMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFETAMET","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cefetamet","Cefetamet pivoxil hydrochloride"],"crossReferences":{"drugbank":["DB13504"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2103823","canonicalSmiles":"O=C([N-]S(=O)(=O)c1ccc(Br)s1)c1ccc(Cl)cc1Cl.[Na+]","inchiKey":"JCOHXVDKRMWUQP-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"TASISULAM SODIUM","maximumClinicalTrialPhase":3,"parentId":"CHEMBL2110587","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-573636 SODIUM","LY-573636.NA","LY-573636NA","Tasisulam sodium"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2103996","canonicalSmiles":"CNCC(=O)c1ccc(O)c(O)c1","inchiKey":"PZMVOUYYNKPMSI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ADRENALONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Adrenalone","Adrenone"],"crossReferences":{"PubChem":["144206663","170466247","99494755"],"drugbank":["DB13394"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2104574","canonicalSmiles":"CCCCC[C@H](O)/C=C/[C@@H]1C(CCCCCCC(=O)OCCCC)=C(OC(=O)CCC)C[C@H]1O","inchiKey":"HITYEEHTEOQBAC-OSIGYOHNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ECRAPROST","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AS-013","Ecraprost"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2105242","canonicalSmiles":"CCN(CC)c1nc(=NN)nc(N(CC)CC)[nH]1","inchiKey":"IRQOBYXMACIFKD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MELADRAZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BA 13155 [AS TARTRATE]","Meladrazine"],"crossReferences":{"drugbank":["DB13272"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2105322","canonicalSmiles":"O=C(O)CSC(SCC(=O)O)SCC(=O)O","inchiKey":"ZBNBQISDCFIEQC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RITIOMETAN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ritiometan"],"crossReferences":{"drugbank":["DB13267"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2105467","canonicalSmiles":"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\\F)c(=O)n1","inchiKey":"GFFXZLZWLOBBLO-ASKVSEFXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEZACITABINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FMD-C","KW-2331","MDL-101731"],"crossReferences":{"drugbank":["DB06433"]},"childChemblIds":["CHEMBL3989496"],"count":5,"linkedTargets":{"rows":["ENSG00000048392","ENSG00000167325","ENSG00000171848"],"count":3},"linkedDiseases":{"rows":["EFO_0003897","EFO_0002916","EFO_0004142","EFO_0000228","EFO_0000311"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2105702","canonicalSmiles":"COc1ccc(F)cc1C[C@@](O)(C1CCOCC1)[C@@H]1CNCCO1.Cl","inchiKey":"WJDKGRLMNSHPON-CJRXIRLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EDIVOXETINE HYDROCHLORIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL2103857","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Edivoxetine hydrochloride","LY2216684 HCL"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106170","canonicalSmiles":"CC(CC1c2ccccc2CCc2ccccc21)CN(C)C.Cl","inchiKey":"MCWAFEJHLHEFOD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BUTRIPTYLINE HYDROCHLORIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL2110816","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AY-62014","Butriptyline hydrochloride"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106224","canonicalSmiles":"Nc1nnnn1-c1ccccc1","inchiKey":"ULIDRMKBVYYVIQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FENAMOLE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AL 0559","Fenamole","P-463","PAT"],"crossReferences":{"PubChem":["170466193"],"drugbank":["DB12506"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106277","canonicalSmiles":"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C","inchiKey":"UWGRWFCLGQWKPR-GSTUPEFVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIFLUCORTOLONE PIVALATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Diflucortolone pivalate","SH 968"],"crossReferences":{"drugbank":["DB14664"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106978","canonicalSmiles":"O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[K+]","inchiKey":"HLCFGWHYROZGBI-JJKGCWMISA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"POTASSIUM GLUCONATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kaon","Katorin"],"synonyms":["E-577","Gluconic acid potassium salt","INS NO.577","INS-577","Potassium gluconate"],"crossReferences":{"DrugCentral":["4524"],"PubChem":["144209972"],"drugbank":["DB13620"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL2107359","canonicalSmiles":"CONC(=N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cc3)o2)cc1.O=C(O)/C=C\\C(=O)O","inchiKey":"SWMNGXODFOCPKQ-BTJKTKAUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PAFURAMIDINE MALEATE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL319669","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DB-289","DB289","Pafuramidine maleate"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2107686","canonicalSmiles":"CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[I-]","inchiKey":"VFEDLMLHAGASHB-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIDIHEXETHYL IODIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1201354","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tridihexethyl iodide"],"crossReferences":{"chEBI":["9704"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2107729","canonicalSmiles":"O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1","inchiKey":"PQHLRGARXNPFCF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ATACIGUAT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ataciguat"],"crossReferences":{"PubChem":["144206754","170466340"],"drugbank":["DB12805"]},"childChemblIds":["CHEMBL4079827"],"count":3,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2107821","canonicalSmiles":"NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1","inchiKey":"WJIGGYYSZBWCGC-MRXNPFEDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EMIXUSTAT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Acu-4429"],"synonyms":["ACU-4429","Emixustat"],"crossReferences":{"drugbank":["DB12608"]},"childChemblIds":["CHEMBL2107829"],"count":3,"linkedTargets":{"rows":["ENSG00000116745"],"count":1},"linkedDiseases":{"rows":["EFO_1001492","EFO_0001365","Orphanet_827","EFO_0009322"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2107882","drugType":"Unknown","blackBoxWarning":false,"name":"RELAXIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Cervilaxin","Releasin"],"synonyms":["Relaxin"],"count":3,"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2108318","drugType":"Protein","blackBoxWarning":false,"name":"ELSIGLUTIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Elsiglutide","ZP-1846","ZP1846","Zp1846"],"count":1,"linkedTargets":{"rows":["ENSG00000065325"],"count":1},"linkedDiseases":{"rows":["HP_0002014"],"count":1},"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2108322","drugType":"Protein","blackBoxWarning":false,"name":"VATREPTACOG ALFA (ACTIVATED)","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NN-1731","NN1731","Vatreptacog alfa (activated)"],"count":2,"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108811","drugType":"Antibody","blackBoxWarning":false,"name":"VISILIZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Nuvion"],"synonyms":["HUM-291","Visilizumab","huM291"],"count":5,"linkedTargets":{"rows":["ENSG00000198851"],"count":1},"linkedDiseases":{"rows":["MONDO_0013730","EFO_0000729","MONDO_0000956","EFO_0000574","EFO_0000384","EFO_0004599"],"count":6},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2108918","drugType":"Unknown","blackBoxWarning":false,"name":"CHAMOMILE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["B2045","Chamomile","Matricaria recutita","Matricaria recutita flower","Matricaria recutita flower dry extract","Matricaria recutita flower extract"],"count":4,"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2109247","drugType":"Antibody","blackBoxWarning":false,"name":"LBY-135","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LBY-135"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2109256","drugType":"Antibody","blackBoxWarning":false,"name":"SGN-30","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SGN-30","Sgn-30"],"count":6,"linkedTargets":{"rows":["ENSG00000120949"],"count":1},"linkedDiseases":{"rows":["EFO_0004708","EFO_0003032","EFO_0000558","EFO_0001642","EFO_0002913","EFO_0000574","EFO_0000183"],"count":7},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL2109352","drugType":"Antibody","blackBoxWarning":false,"name":"BL22","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BL22","Bl22","CAT-3888"],"count":3,"linkedTargets":{"rows":["ENSG00000012124"],"count":1},"linkedDiseases":{"rows":["EFO_0000565","EFO_1000956","EFO_0000574"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2109427","drugType":"Antibody","blackBoxWarning":false,"name":"ZOLBETUXIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Claudiximab","IMAB-362","IMAB362","Zolbetuximab"],"count":1,"linkedTargets":{"rows":["ENSG00000066405"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_1000044"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2109484","drugType":"Antibody","blackBoxWarning":false,"name":"BB-10901","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BB-10901","HUN901-DM1"],"count":2,"linkedTargets":{"rows":["ENSG00000149294"],"count":1},"linkedDiseases":{"rows":["EFO_0000702","EFO_0001378"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2141296","canonicalSmiles":"CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O","inchiKey":"MXAYKZJJDUDWDS-LBPRGKRZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IXAZOMIB","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ninlaro"],"synonyms":["Ixazomib","MLN-2238","MLN-9708 FREE BASE","MLN2238"],"crossReferences":{"PubChem":["124955652"],"drugbank":["DB09570"]},"count":21,"approvedIndications":["EFO_0000616","EFO_0000311"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and cancer and has 19 investigational indications."}
{"id":"CHEMBL2146090","canonicalSmiles":"CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\\[C@@H]2C[C@@]2(C(=O)[N-]S(=O)(=O)C2CC2)NC(=O)[C@@H]2C[C@@H](OC(=O)N3Cc4cccc(F)c4C3)CN2C1=O.[Na+]","inchiKey":"GXYYUDQAGCVAGJ-HHGSPMIASA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"DANOPREVIR SODIUM","maximumClinicalTrialPhase":0,"parentId":"CHEMBL258734","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Danoprevir sodium","ITMN-191","R7227","RO5190591-001"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL21536","canonicalSmiles":"CCCCCCOc1nsnc1C1=CCCN(C)C1","inchiKey":"JOLJIIDDOBNFHW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"XANOMELINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Xanomeline"],"crossReferences":{"Wikipedia":["Xanomeline"],"drugbank":["DB15357"],"chEBI":["10056"]},"childChemblIds":["CHEMBL2336050","CHEMBL73149"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL216913","canonicalSmiles":"CC(/C=N/N=C(N)N)=N\\N=C(N)N","inchiKey":"MXWHMTNPTTVWDM-NXOFHUPFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MITOGUAZONE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mitoguazone"],"crossReferences":{"drugbank":["DB12967"],"chEBI":["43996"]},"childChemblIds":["CHEMBL1995011"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2179105","canonicalSmiles":"C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1","inchiKey":"IWXUVYOOUMLUTQ-CZUORRHYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-04447943","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pf-04447943"],"crossReferences":{"drugbank":["DB11953"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL24171","canonicalSmiles":"COc1c2ccoc2cc2oc(=O)ccc12","inchiKey":"BGEBZHIAGXMEMV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BERGAPTEN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["5-methoxypsoralen","Bergapten","NSC-95437"],"crossReferences":{"PubChem":["11113276","144209555","144213572","17389221","26747383","400239","50105624","85148739"],"Wikipedia":["Bergapten"],"drugbank":["DB12216"]},"count":2,"approvedIndications":["EFO_0000676"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psoriasis and has 1 investigational indication."}
{"id":"CHEMBL2430359","canonicalSmiles":"CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O.O=S(=O)(O)c1ccccc1","inchiKey":"LKLWTLXTOVZFAE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2430359","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1084546","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL245416","canonicalSmiles":"N[C@@H](Cn1ccc(=O)c(O)c1)C(=O)O","inchiKey":"WZNJWVWKTVETCG-YFKPBYRVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"L-MIMOSINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["L-Mimosine"],"crossReferences":{"PubChem":["90340685"],"drugbank":["DB01055"],"chEBI":["29063"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL24924","canonicalSmiles":"O=C1c2ccccc2C(=O)C1c1ccc(F)cc1","inchiKey":"NASXCEITKQITLD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUINDIONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Previscan"],"synonyms":["Fluindione"],"crossReferences":{"PubChem":["144205432","29216219"],"drugbank":["DB13136"]},"count":1,"approvedIndications":["HP_0004419"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis."}
{"id":"CHEMBL255066","canonicalSmiles":"CCOC(=O)COc1ccc2c(C)c(CCN(CC)CC)c(=O)oc2c1Cl","inchiKey":"GYNNRVJJLAVVTQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLORICROMEN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cloricromen"],"crossReferences":{"PubChem":["29217526","50111702"],"Wikipedia":["Cloricromen"],"drugbank":["DB13367"]},"childChemblIds":["CHEMBL2354840"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL263881","canonicalSmiles":"CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1","inchiKey":"VAYOSLLFUXYJDT-RDTXWAMCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LYSERGIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LSD","Lysergic acid diethylamide","Lysergic acid diethylamide tartrate ci","Lysergide"],"crossReferences":{"PubChem":["144206425","144207057","50113078"],"Wikipedia":["Lysergic_acid_diethylamide"],"drugbank":["DB04829"],"chEBI":["6605"]},"childChemblIds":["CHEMBL463207","CHEMBL269421"],"count":3,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL27577","canonicalSmiles":"NC(=O)c1ccccc1O","inchiKey":"SKZKKFZAGNVIMN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SALICYLAMIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Salicylamide"],"crossReferences":{"PubChem":["144204680","144209142","144213118","170465496","17389647","26747354","8139933"],"Wikipedia":["Salicylamide"],"drugbank":["DB08797"],"chEBI":["32114"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL278398","canonicalSmiles":"CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12","inchiKey":"ISFHAYSTHMVOJR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENINDAMINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Nolahist","Phenindamine","Thephorin"],"crossReferences":{"Wikipedia":["Phenindamine"],"drugbank":["DB01619"],"chEBI":["8065"]},"childChemblIds":["CHEMBL2107213"],"count":1,"approvedIndications":["EFO_0003785"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for allergy."}
{"id":"CHEMBL280051","canonicalSmiles":"CCCCc1nc2c(=O)[nH][nH]c(=O)c2[nH]1","inchiKey":"DQHJYYALMHIEAH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL280051","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02441"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL297884","canonicalSmiles":"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)C[C@H]5/C=C\\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(C)C)n3)nc2c1","inchiKey":"PJZPDFUUXKKDNB-KNINVFKUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CILUPREVIR","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BILN 2061 ZW","BILN-2061","BILN-2061-ZW","Ciluprevir"],"crossReferences":{"Wikipedia":["Ciluprevir"],"drugbank":["DB05868"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3039511","canonicalSmiles":"COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1","inchiKey":"ZGCYVRNZWGUXNQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BEVENOPRAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADL-5945","ADL5945","Bevenopran","CB-5945","CB5-945","CB5945"],"crossReferences":{"drugbank":["DB12464"]},"count":2,"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0003086","HP_0002019"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3112741","canonicalSmiles":"O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O","inchiKey":"SMOBCLHAZXOKDQ-ZJUUUORDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RELEBACTAM","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"crossReferences":{"DailyMed":["relebactam"],"drugbank":["DB12377"]},"childChemblIds":["CHEMBL3301605","CHEMBL4516632"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019."}
{"id":"CHEMBL3137333","canonicalSmiles":"CNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1.O=S(=O)([O-])O","inchiKey":"LWXUIUUOMSMZKJ-KLFWAVJMSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"ISAVUCONAZONIUM SULFATE","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1183349","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cresemba"],"synonyms":["AK-1820","AK1820","Ak1820","BAL-8557-002","BAL8557-002","Isavuconazonium sulfate"],"crossReferences":{"DailyMed":["isavuconazonium%20sulfate"],"chEBI":["85977"]},"count":4,"approvedIndications":["EFO_0007157","EFO_0007380"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for mucormycosis and aspergillosis and has 2 investigational indications."}
{"id":"CHEMBL3187723","canonicalSmiles":"Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21","inchiKey":"ACWZRVQXLIRSDF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BINIMETINIB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mektovi"],"synonyms":["ARRY 438162","ARRY-162","ARRY-438162","Binimetinib","MEK-162","MEK162","Mek-162","NVP-MEK162"],"crossReferences":{"DailyMed":["binimetinib"],"PubChem":["174006430"],"drugbank":["DB11967"]},"count":24,"approvedIndications":["EFO_0000616","EFO_0000756","EFO_0000389","EFO_0002617","EFO_0000311"],"linkedTargets":{"rows":["ENSG00000126934","ENSG00000169032"],"count":2},"linkedDiseases":{"rows":["EFO_0000756","EFO_0002503","MONDO_0007254","EFO_1000657","MONDO_0021063","MONDO_0002087","EFO_0000305","EFO_1001951","EFO_0000565","EFO_1001480","MONDO_0002158","EFO_1000044","EFO_1000956","EFO_0000389","MONDO_0008903","EFO_0002617","EFO_0000616","EFO_0002618","EFO_0000685","EFO_1000616","MONDO_0008170","Orphanet_44890","EFO_0000313","EFO_0003060","EFO_0000311","EFO_0000304","EFO_0002892","EFO_0001421","EFO_0001378","MONDO_0021637"],"count":30},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 19 investigational indications."}
{"id":"CHEMBL3217110","canonicalSmiles":"COc1cc(NC(C)CCCN)c2ncccc2c1.Cl.Cl","inchiKey":"STKZOTIORLKRFH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3217110","maximumClinicalTrialPhase":0,"parentId":"CHEMBL506","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3245937","canonicalSmiles":"C=CCOc1ccccc1OCC(O)CNC(C)C.O=C(O)C(F)(F)F","inchiKey":"RIQMJBDLMFLUIF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3245937","maximumClinicalTrialPhase":0,"parentId":"CHEMBL546","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3301598","canonicalSmiles":"COc1cnc(-n2cnc(C)n2)c2c1c(C(=O)C(=O)N1CCN(C(=O)c3ccccc3)CC1)cn2COP(=O)(O)O.NC(CO)(CO)CO","inchiKey":"RRGJSMBMTOKHTE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FOSTEMSAVIR TROMETHAMINE","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3301594","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Rukobia"],"synonyms":["BMS-663068-03","Fostemsavir tromethamine","GSK3684934A"],"crossReferences":{"DailyMed":["fostemsavir%20tromethamine"]},"count":1,"approvedIndications":["EFO_0000180"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for hiv-1 infection."}
{"id":"CHEMBL3301603","canonicalSmiles":"CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O","inchiKey":"UJOUWHLYTQFUCU-WXXKFALUSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"GILTERITINIB FUMARATE","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3301622","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Xospata"],"synonyms":["ASP-2215 HEMIFUMARATE","ASP2215 hemifumarate","Gilteritinib fumarate"],"crossReferences":{"DailyMed":["gilteritinib%20fumarate"]},"count":1,"approvedIndications":["EFO_0000222"],"linkedTargets":{"rows":["ENSG00000167601","ENSG00000122025"],"count":2},"linkedDiseases":{"rows":["EFO_0000222"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for acute myeloid leukemia. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3301667","canonicalSmiles":"[Ca+2].[N-]=C=[N-]","inchiKey":"MYFXBBAEXORJNB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CALCIUM CARBIMIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL116583","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Calcium carbimide","Carbodimid calcium","Cyanamide"],"crossReferences":{"DrugCentral":["4432"],"drugbank":["DB09116"],"chEBI":["64301"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3354594","canonicalSmiles":"CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCSC[C@@H](C(=O)N(CC(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)Cc2ccc(F)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O","inchiKey":"PVVHQWISMVJHFK-NIFJBHDKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3354594","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB12932"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3358920","canonicalSmiles":"O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21","inchiKey":"MVGWUTBTXDYMND-QGZVFWFLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETRASIMOD","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["APD-334","APD-334(FREE ACID)","APD334","Apd334","Etrasimod"],"crossReferences":{"drugbank":["DB14766"]},"childChemblIds":["CHEMBL3989933"],"count":6,"linkedTargets":{"rows":["ENSG00000170989"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0004192","HP_0000999","EFO_0000274","EFO_1001486","EFO_0000384","EFO_0003767"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL341273","canonicalSmiles":"Clc1cccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)c1","inchiKey":"OUEGMEMDEAOAEG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL341273","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07203"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL342672","canonicalSmiles":"N=C(N)NCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC=O)CNC(=O)/C=C/[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)C1=O","inchiKey":"CDWXSPKJKIUEQF-BIXWYCRZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CYCLOTHEONAMIDE A","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04269"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3527416","canonicalSmiles":"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(OCCO)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O","inchiKey":"MBHXKZDTQCSVPM-BDAFLREQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MONOXERUTIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Monoxerutin"],"crossReferences":{"drugbank":["DB13764"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545189","drugType":"Antibody","blackBoxWarning":false,"name":"LANADELUMAB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Takhzyro"],"synonyms":["DX-2930","Lanadelumab","Lanadelumab (shp643)","SHP-643"],"crossReferences":{"DailyMed":["lanadelumab%20(shp643)"]},"count":2,"approvedIndications":["Orphanet_91378"],"linkedTargets":{"rows":["ENSG00000164344"],"count":1},"linkedDiseases":{"rows":["MONDO_0100096","EFO_0005532","Orphanet_91378"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for hereditary angioedema and has 1 investigational indication."}
{"id":"CHEMBL3545216","drugType":"Small molecule","blackBoxWarning":false,"name":"FX-005","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fx-005"],"count":1,"linkedTargets":{"rows":["ENSG00000112062"],"count":1},"linkedDiseases":{"rows":["EFO_0004616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545283","canonicalSmiles":"CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C1CO","inchiKey":"QLUYMIVVAYRECT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIVICICLIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["P276-00","Riviciclib"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3545349","canonicalSmiles":"Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1.Cl.Cl","inchiKey":"OJBLXSPBJMGZDN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EVT-101","maximumClinicalTrialPhase":2,"parentId":"CHEMBL3545350","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Evt-101"],"crossReferences":{"drugbank":["DB05956"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3545400","drugType":"Small molecule","blackBoxWarning":false,"name":"SAR-103168","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sar-103168"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL358866","canonicalSmiles":"CC(=O)N[C@@H](Cc1ccc(C(=O)O)c(C=O)c1)C(=O)N[C@H]1CCCCN(Cc2ccc(-c3ccccc3)cc2)C1=O","inchiKey":"WKTQBTSOHBKBRW-VMPREFPWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL358866","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03268"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL36342","canonicalSmiles":"CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1.Cl.Cl","inchiKey":"SMGTYJPMKXNQFY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OCTENIDINE HYDROCHLORIDE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL1199480","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LAS-189962","LAS189962","Octenidine","Octenidine dihydrochloride","Octenidine hydrochloride","WIN 41464-2","WIN-41464-2"],"count":4,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL367149","canonicalSmiles":"CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O","inchiKey":"MBMBGCFOFBJSGT-KUBAVDMBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DOCONEXENT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Doconexent","Docosahexaenoic acid","Omega-3 marine triglycerides"],"crossReferences":{"PubChem":["144205545","26754926","26754927","26754928","50110834"],"Wikipedia":["Docosahexaenoic_acid"],"drugbank":["DB03756"],"chEBI":["28125"]},"count":44,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 44 investigational indications."}
{"id":"CHEMBL370143","canonicalSmiles":"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O","inchiKey":"UOZODPSAJZTQNH-LSWIJEOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PAROMOMYCIN","yearOfFirstApproval":1969,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["ANTIBIOTIC 503-3","ANTIBIOTIC SF 767B","Aminosidine","Monomycin","Paromomycin","R 400","R-400"],"crossReferences":{"DailyMed":["paromomycin%20sulfate"],"Wikipedia":["Paromomycin"],"drugbank":["DB01421"],"chEBI":["7934"]},"childChemblIds":["CHEMBL2206196"],"count":4,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 4 investigational indications."}
{"id":"CHEMBL3707183","canonicalSmiles":"C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O","inchiKey":"ZHNFLHYOFXQIOW-AHSOWCEXSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"QUINIDINE SULFATE","yearOfFirstApproval":1962,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1294","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cin-quin","Quinicardine","Quinidex","Quinidine sulfate","Quinora"],"synonyms":["AVP-786 COMPONENT QUINIDINE SULFATE","NSC-10004","QUINIDINE SULFATE COMPONENT OF AVP-786","Quinidine sulfate","Quinidine sulfate anhydrous","Quinidine sulfate dihydrate","Quinidine sulfate hydrate"],"crossReferences":{"DailyMed":["quinidine%20sulfate"]},"count":2,"linkedTargets":{"rows":["ENSG00000185313","ENSG00000153253","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000136531","ENSG00000007314","ENSG00000196876"],"count":10},"linkedDiseases":{"rows":["EFO_0000249","EFO_0003758","EFO_0000253"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3707267","canonicalSmiles":"C[C@]1([18F])C[C@@](N)(C(=O)O)C1","inchiKey":"ILMJJAKSEOUEPX-DZQYMRDVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUCICLOVINE F18","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3707268","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Axumin","Axumin"],"synonyms":["FACBC","Fluciclovine (18f)","Fluciclovine f 18","Fluciclovine f-18","Fluciclovine f18","GE-148","GE-148 (18F)","GE-148 F-18","NMK-36","NMK36"],"crossReferences":{"DailyMed":["fluciclovine%20f-18"]},"count":3,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 investigational indications."}
{"id":"CHEMBL3707330","canonicalSmiles":"C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.O","inchiKey":"GZQWMYVDLCUBQX-WVZIYJGPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ROLAPITANT HYDROCHLORIDE","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3707331","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Varubi"],"synonyms":["Rolapitant hydrochloride","Rolapitant hydrochloride monohydrate","SCH-619734","SCH619734"],"crossReferences":{"DailyMed":["rolapitant%20hydrochloride"]},"count":2,"approvedIndications":["EFO_0006911"],"linkedTargets":{"rows":["ENSG00000115353"],"count":1},"linkedDiseases":{"rows":["EFO_0006911","EFO_0000691"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for chemotherapy-induced nausea and vomiting and has 1 investigational indication."}
{"id":"CHEMBL377312","canonicalSmiles":"O=c1[nH]c2ccc(Cl)cc2c(N[C@@H]2C[N@]3CC[C@H]2CC3)c1-c1nc2ccccc2[nH]1","inchiKey":"MOVBBVMDHIRCTG-LJQANCHMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL377312","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06852"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3833310","canonicalSmiles":"O.O[Al](O)O","inchiKey":"SMYKVLBUSSNXMV-UHFFFAOYSA-K","drugType":"Small molecule","blackBoxWarning":false,"name":"ALGELDRATE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1200706","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Algeldrate","W 4600"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL384200","canonicalSmiles":"CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC","inchiKey":"VQFKFAKEUMHBLV-BYSUZVQFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RGI-7000","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AGL-582","KRN-7000","KRN7000","Krn7000","RGI-7000","Rgi-7000"],"crossReferences":{"drugbank":["DB12232"],"chEBI":["466659"]},"count":4,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3884248","canonicalSmiles":"Cc1ncc([N+](=O)[O-])n1CC(O)CN1CCOCC1","inchiKey":"GAZGHCHCYRSPIV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MORINIDAZOLE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Morinidazole"],"crossReferences":{"drugbank":["DB15098"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3989695","canonicalSmiles":"CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O","inchiKey":"CDQVVPUXSPZONN-WPPLYIOHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"REGADENOSON","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL317052","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lexiscan"],"synonyms":["CVT-3146","Regadenoson"],"crossReferences":{"DailyMed":["regadenoson"]},"count":1,"approvedIndications":["EFO_0000319"],"linkedTargets":{"rows":["ENSG00000128271"],"count":1},"linkedDiseases":{"rows":["EFO_0000319"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008 and is indicated for cardiovascular disease."}
{"id":"CHEMBL3989867","canonicalSmiles":"O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c([O-])c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2.[Na+]","inchiKey":"WJNFBIVCQMPPJC-FQYDJHLKSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"BICTEGRAVIR SODIUM","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3989866","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Bictegravir sodium","GS-9883","GS-9883-01"],"crossReferences":{"DailyMed":["bictegravir%20sodium"]},"count":1,"approvedIndications":["EFO_0000180"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for hiv-1 infection."}
{"id":"CHEMBL3990028","drugType":"Antibody","blackBoxWarning":false,"name":"BLESELUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ASKP-1240","ASKP1240","Bleselumab"],"count":2,"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL405957","canonicalSmiles":"OC[C@@H]1N[C@@H](CO)[C@H](O)[C@H]1O","inchiKey":"PFYHYHZGDNWFIF-BXKVDMCESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL405957","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02172"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL408403","canonicalSmiles":"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O","inchiKey":"CZGUSIXMZVURDU-JZXHSEFVSA-N","drugType":"Protein","blackBoxWarning":false,"name":"ANGIOTENSIN II","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Angiotensin ii","Angiotensin ii (human type)","LJPC-501"],"crossReferences":{"DailyMed":["angiotensin%20ii%20acetate"],"PubChem":["50112427"],"drugbank":["DB11842"],"chEBI":["2719"]},"childChemblIds":["CHEMBL4303682","CHEMBL3989932"],"count":5,"approvedIndications":["EFO_0000319"],"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["HP_0000083","EFO_0006834","EFO_0005252","EFO_0000319","EFO_0000537"],"count":5},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for cardiovascular disease and has 4 investigational indications."}
{"id":"CHEMBL4101392","canonicalSmiles":"CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1.[Na+]","inchiKey":"YOBPSXOHCHDCMU-VKZZUTNHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL4101392","maximumClinicalTrialPhase":0,"parentId":"CHEMBL161","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL417990","canonicalSmiles":"CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3","inchiKey":"IYGYMKDQCDOMRE-ZWKOTPCHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BICUCULLINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(+)-Bicuculline","Bicuculline"],"crossReferences":{"PubChem":["56463577"],"Wikipedia":["Bicuculline"],"drugbank":["DB11562"],"chEBI":["3092"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL424133","canonicalSmiles":"Cc1ccc(Cn2nc(CCCc3ccc(OC(C)(C)C(=O)O)cc3)nc2O)cc1","inchiKey":"PNHFDVSKDSLUFH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LY-518674","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["KB-68984","LY-674","LY518674","Ly-518674"],"crossReferences":{"drugbank":["DB12988"]},"count":3,"linkedTargets":{"rows":["ENSG00000186951"],"count":1},"linkedDiseases":{"rows":["EFO_0000195","HP_0003124","EFO_0000537"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL427683","canonicalSmiles":"COc1ccc(C)c(OC(CCN2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(C)C)c1","inchiKey":"HDTXDTWVQLQAMW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ORGANON","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Organon"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4279521","canonicalSmiles":"Cc1nn(-c2cnc(OCC(C)C)c(Cl)c2)c2ccc(C(=O)NS(C)(=O)=O)cc12","inchiKey":"RVTSXVZXEGFIPW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-05241328","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pf-05241328"],"crossReferences":{"drugbank":["DB15124"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4289017","canonicalSmiles":"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12","inchiKey":"RYYNGWLOYLRZLK-RBUKOAKNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL4289017","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB13059"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297079","canonicalSmiles":"CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO","inchiKey":"XSGHHWMGNIMZCA-FPOQQNBBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DOBUTAMINE LACTOBIONATE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL926","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dobutamine lactobionate"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297317","canonicalSmiles":"C[C@@H](C(N)=O)[C@H](N)c1nc2ccc(C(C)(C)C)cc2[nH]1","inchiKey":"APWZIFIAVVFPNT-PELKAZGASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-06305591","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF-6305591","Pf-06305591"],"crossReferences":{"drugbank":["DB12106"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297330","canonicalSmiles":"CC(C)=CCCC(C)=CCCC(C)=CCCC1(C)CCc2cc(O)ccc2O1","inchiKey":"GJJVAFUKOBZPCB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TOCOTRIENOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tocotrienol"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297428","canonicalSmiles":"CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O","inchiKey":"GJLXVWOMRRWCIB-MERZOTPQSA-N","drugType":"Protein","blackBoxWarning":false,"name":"SER-100","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SER100","Ser-100","Ser100","ZP 120"],"count":1,"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297526","canonicalSmiles":"COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21","inchiKey":"CYHWMBVXXDIZNZ-KRWDZBQOSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"REMIMAZOLAM","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Byfavo"],"synonyms":["CNS 7056","CNS-7056","Cns 7056","ONO-2745","Remimazolam"],"crossReferences":{"DailyMed":["remimazolam%20besylate"],"drugbank":["DB12404"]},"childChemblIds":["CHEMBL4297324","CHEMBL4594301"],"count":2,"linkedTargets":{"rows":["ENSG00000182256","ENSG00000022355","ENSG00000011677","ENSG00000163285","ENSG00000113327","ENSG00000151834","ENSG00000186297"],"count":7},"linkedDiseases":{"rows":["EFO_0003890","EFO_0001421","EFO_0009267"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4297857","drugType":"Unknown","blackBoxWarning":false,"name":"AB-928","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AB-928","AB928","Ab-928","Ab928"],"count":2,"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297863","drugType":"Antibody","blackBoxWarning":false,"name":"REMTOLUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["A-1230717","ABT-122","Abt-122","Remtolumab"],"count":2,"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297959","drugType":"Unknown","blackBoxWarning":false,"name":"KONJAC MANNAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Glucomannan","Konjac mannan"],"count":2,"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297972","drugType":"Unknown","blackBoxWarning":false,"name":"GWN-323","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GWN-323","GWN323","Gwn-323","Gwn323"],"count":1,"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4298184","drugType":"Antibody","blackBoxWarning":false,"name":"MAFTIVIMAB","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Maftivimab","REGN3479"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4476214","canonicalSmiles":"[2H]C([2H])([2H])c1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1","inchiKey":"GSNHKUDZZFZSJB-KEIMLNMFSA-N","drugType":"unknown","blackBoxWarning":false,"name":"CHEMBL4476214","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1201187","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Unknown drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594470","drugType":"Unknown","blackBoxWarning":false,"name":"CVX-060","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CVX-060","CVX060","Cvx-060","PF-04856884","PF04856884","Pf-04856884"],"count":3,"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4594484","drugType":"Unknown","blackBoxWarning":false,"name":"OBI-888","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["OBI-888","Obi-888"],"count":1,"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594524","drugType":"Unknown","blackBoxWarning":false,"name":"TRIS(8-HYDROXYQUINOLINATO)GALLIUM","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AP-002","Ap-002","IT-235","LX-001","NKP-2235","Tris(8-hydroxyquinolinato)gallium"],"count":1,"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594529","drugType":"Antibody","blackBoxWarning":false,"name":"NURULIMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BCD-145","BCD145","Bcd-145","Nurulimab"],"count":1,"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594531","drugType":"Unknown","blackBoxWarning":false,"name":"BI-836826","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BI 836826","BI-836826","Bi 836826","Bi-836826"],"count":3,"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4594564","drugType":"Antibody","blackBoxWarning":false,"name":"TESNATILIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Jnj-64304500","Tesnatilimab"],"count":1,"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL460566","canonicalSmiles":"Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c([O-])c(=O)n2C)o1.[Na+]","inchiKey":"QLBNDXLKPYXCIW-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL460566","maximumClinicalTrialPhase":0,"parentId":"CHEMBL254316","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL479","canonicalSmiles":"CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2","inchiKey":"KLBQZWRITKRQQV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"THIORIDAZINE","yearOfFirstApproval":1962,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," Worldwide"],"classes":["Cardiotoxicity"],"year":2005},"tradeNames":["Mellaril","Mellaril-s","Melleril","Rideril"],"synonyms":["Mellaril","TP-21","Thioridazine"],"crossReferences":{"DailyMed":["thioridazine%20hydrochloride"],"PubChem":["104171257","124881748","144203845","170465080","174006671","26752322","50105272","90341630"],"TG-GATEs":["38"],"Wikipedia":["Thioridazine"],"drugbank":["DB00679"],"chEBI":["9566"]},"childChemblIds":["CHEMBL1200916"],"count":6,"approvedIndications":["EFO_0005407"],"linkedTargets":{"rows":["ENSG00000069696","ENSG00000149295","ENSG00000102468","ENSG00000151577","ENSG00000147246"],"count":5},"linkedDiseases":{"rows":["MONDO_0002050","HP_0000726","EFO_0000222","EFO_0005407","EFO_0005230","EFO_0005411","EFO_0000692"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and is indicated for psychosis and has 5 investigational indications. It was withdrawn in United Kingdom and  Worldwide initially in 2005 due to Cardiotoxicity. This drug has a black box warning from the FDA."}
{"id":"CHEMBL481854","canonicalSmiles":"C[C@@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]4(C)[C@]3(C)CC[C@@]2(C(=O)O)CC[C@H]1C","inchiKey":"PRAUVHZJPXOEIF-AOLYGAPISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MADECASSIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-88135"],"crossReferences":{"drugbank":["DB14037"],"chEBI":["73058"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL481958","canonicalSmiles":"CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O.Cl","inchiKey":"BHMLHEQFWVQAJS-IITOGVPQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMRUBICIN HYDROCHLORIDE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL1186894","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Amrubicin hydrochloride","SM 5887","SM-5887"],"count":2,"linkedTargets":{"rows":["ENSG00000131747"],"count":1},"linkedDiseases":{"rows":["MONDO_0008903","EFO_0000702"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL482767","canonicalSmiles":"O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1","inchiKey":"FAYAUAZLLLJJGH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SNS-314","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SNS-314","Sns 314","Sns-314"],"crossReferences":{"PubChem":["103905586","124950687"],"drugbank":["DB06134"]},"childChemblIds":["CHEMBL518051"],"count":1,"linkedTargets":{"rows":["ENSG00000087586","ENSG00000178999","ENSG00000105146"],"count":3},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL486208","canonicalSmiles":"CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](O)C2","inchiKey":"DTGKSKDOIYIVQL-WEDXCCLWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BORNEOL","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(-) Borneol","Borneol","FEMA NO. 2157","NSC-60223"],"crossReferences":{"Wikipedia":["Borneol"],"chEBI":["15393"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL48802","canonicalSmiles":"C[S+]([O-])CCCCN=C=S","inchiKey":"SUVMJBTUFCVSAD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFORAPHANE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-(Methylsulfinyl)Butyl Isothiocyanate","Sulforaphane"],"crossReferences":{"Wikipedia":["Sulforaphane"],"chEBI":["47807"]},"count":13,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."}
{"id":"CHEMBL493287","canonicalSmiles":"N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O","inchiKey":"MSWZFWKMSRAUBD-IVMDWMLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GLUCOSAMINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Glucosamine"],"crossReferences":{"drugbank":["DB01296"],"chEBI":["47977"]},"childChemblIds":["CHEMBL3989618","CHEMBL3989750","CHEMBL3989707","CHEMBL1707007"],"count":6,"approvedIndications":["EFO_0005755"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for rheumatic disease and has 5 investigational indications."}
{"id":"CHEMBL501867","canonicalSmiles":"CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O","inchiKey":"AQTQHPDCURKLKT-JKDPCDLQSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"VINCRISTINE SULFATE","yearOfFirstApproval":1963,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL90555","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kyocristine","Leurocristine Sulfate","Marqibo kit","Oncovin","Vincasar","Vincasar pfs","Vincrex","Vincristine sulfate","Vincristine sulfate pfs"],"synonyms":["37231","LILLY-37231","NSC-67574","Vincristine sulfate"],"crossReferences":{"PubChem":["112141"],"chEBI":["79401"]},"count":56,"linkedTargets":{"rows":["ENSG00000261456","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000258947","ENSG00000101162","ENSG00000137285","ENSG00000196230","ENSG00000176014"],"count":9},"linkedDiseases":{"rows":["MONDO_0000873","EFO_0004708","EFO_0000558","EFO_0000756","EFO_1000131","EFO_0005952","EFO_1001951","EFO_0000565","EFO_0000309","EFO_0000588","EFO_0000096","MONDO_0002974","HP_0001871","MONDO_0019088","MONDO_0008903","MONDO_0015540","EFO_0002918","EFO_0000094","Orphanet_654","EFO_0009441","EFO_1000292","EFO_0000220","MONDO_0018271","EFO_0000248","EFO_0002939","Orphanet_636","EFO_1001946","EFO_1001365","MONDO_0044889","EFO_0003032","MONDO_0044917","EFO_0000574","EFO_0001378","MONDO_0009348","MONDO_0019471","Orphanet_790","EFO_1001469","EFO_0000209","MONDO_0003541","EFO_0000272","EFO_0004289","EFO_0000183","MONDO_0020743","MONDO_0002083","MONDO_0002618","EFO_1000158","EFO_0000616","EFO_0000765","EFO_1000616","EFO_0006859","EFO_0000437","EFO_0000403","EFO_1001042","EFO_0000222","MONDO_0000870","EFO_0000313","EFO_0000621","EFO_0000211","EFO_0000095","EFO_0005235","EFO_0000174","EFO_1001936","EFO_1001947","MONDO_0002367","MONDO_0018906","EFO_0003833","EFO_0000691","MONDO_0021637"],"count":68},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 56 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL501942","canonicalSmiles":"Oc1c(Br)cc(Oc2ccccc2)cc1Br","inchiKey":"CRSZEDOZGJPOHP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL501942","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08103"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL520642","canonicalSmiles":"Nc1nc(/C(=N/O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(/C=C4\\CCN([C@@H]5CCNC5)C4=O)CS[C@H]23)ns1","inchiKey":"VOAZJEPQLGBXGO-SDAWRPRTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFTOBIPROLE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAL-9141-000","BAL-9141000","BAL9141-000","Ceftobiprole","RO 63-9141","RO-63-9141","RO-639141","Zeftera","Zevtera"],"crossReferences":{"Wikipedia":["Ceftobiprole"],"drugbank":["DB04918"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL523","canonicalSmiles":"O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1","inchiKey":"AKPLHCDWDRPJGD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NORDAZEPAM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Calmday","Madar","Stilny","Vegesan"],"synonyms":["Desmethyldiazepam","Desoxydemoxepam","Nordazepam","Nordiazepam"],"crossReferences":{"PubChem":["144207042","49647614"],"Wikipedia":["Nordazepam"],"drugbank":["DB14028"],"chEBI":["111762"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL541887","canonicalSmiles":"CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl","inchiKey":"GURKHSYORGJETM-WAQYZQTGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IRINOTECAN HYDROCHLORIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL481","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["irinotecan"],"crossReferences":{"PubChem":["144205032","170464824","26749086","487652"],"chEBI":["5971"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL574","canonicalSmiles":"Cc1ccc(S(N)(=O)=O)cc1","inchiKey":"LMYRWZFENFIFIT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"P-TOLUENESULFONAMIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-9908","P-toluenesulfonamide","Para-toluenesulfonamide","Paratoulene sulfonamide"],"crossReferences":{"PubChem":["144208792","144213814","17388752","26753007","49675005","75262"],"chEBI":["34435"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL594840","canonicalSmiles":"CC(C)(C)c1onc(OCP(=O)(O)O)c1C[C@H](N)C(=O)O","inchiKey":"AGSOOCUNMTYPSE-ZETCQYMHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL594840","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02347"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL61511","canonicalSmiles":"O=P1(N(CCCl)CCCl)NC(OO)CCO1","inchiKey":"VPAWVRUHMJVRHU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PERFOSFAMIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Pergamid"],"synonyms":["4-HC","4-hydroperoxycyclophosphamide","NSC-181815","Perfosfamide"],"crossReferences":{"PubChem":["124955650","144207157"],"chEBI":["196991"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL69308","canonicalSmiles":"CC(C(=O)O)c1ccc(/C=C2\\CCCCC2=O)cc1","inchiKey":"AUZUGWXLBGZUPP-GXDHUFHOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PELUBIPROFEN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CS-670","Pelubiprofen","RS-2131"],"crossReferences":{"PubChem":["124894216","144206823"],"drugbank":["DB12150"]},"count":3,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL70663","canonicalSmiles":"Cc1cc(C)c(Nc2ccnc(Nc3ccc(C#N)cc3)n2)c(C)c1","inchiKey":"ILAYIAGXTHKHNT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DAPIVIRINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AIDS-105293","Dapivirine","R-147681","TMC-120"],"crossReferences":{"drugbank":["DB08639"]},"childChemblIds":["CHEMBL1257032"],"count":4,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL74415","canonicalSmiles":"CCCCCc1cc(O)c2c(c1)OC(C)(C)c1ccc(C)cc1-2","inchiKey":"VBGLYOIFKLUMQG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CANNABINOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cannabinol","NSC-134455"],"crossReferences":{"PubChem":["144207035"],"Wikipedia":["Cannabinol"],"drugbank":["DB14737"],"chEBI":["3360"]},"count":23,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 23 investigational indications."}
{"id":"CHEMBL76","canonicalSmiles":"CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12","inchiKey":"WHTVZRBIWZFKQO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLOROQUINE","yearOfFirstApproval":1949,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Aralen","Chlorochine","Chloroquine","NSC-187208"],"crossReferences":{"DailyMed":["chloroquine%20phosphate"],"PubChem":["124879700","124879705","174006958","50111008","90340711"],"Wikipedia":["Chloroquine"],"drugbank":["DB00608"],"chEBI":["3638"]},"childChemblIds":["CHEMBL1326","CHEMBL58510","CHEMBL4297165","CHEMBL2095223","CHEMBL1669","CHEMBL2052012"],"count":20,"approvedIndications":["EFO_0001068"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1949 and is indicated for malaria and has 19 investigational indications."}
{"id":"CHEMBL799","canonicalSmiles":"O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1","inchiKey":"RRGUKTPIGVIEKM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CILOSTAZOL","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cilostazol","Pletal"],"synonyms":["Cilostazol","OPC-13013","OPC-21"],"crossReferences":{"DailyMed":["cilostazol"],"PubChem":["104171123","11110906","11113335","124879546","144203649","170465347","174007041","26719653","26719654","26746958","26746959","50100194","50103999","50104000","56463107","85230957","855683","90341176"],"Wikipedia":["Cilostazol"],"drugbank":["DB01166"],"chEBI":["31401"]},"count":10,"approvedIndications":["HP_0004419"],"linkedTargets":{"rows":["ENSG00000172572"],"count":1},"linkedDiseases":{"rows":["EFO_0008493","HP_0002140","HP_0003124","EFO_0003875","EFO_0001645","EFO_0000401","EFO_0000249","MONDO_0002679","EFO_0000556","EFO_0000319","EFO_0003774","EFO_0003876","EFO_0003843","EFO_1001145","EFO_0003914","EFO_0009562","HP_0100543","EFO_0000713","EFO_1000820","EFO_0003870","EFO_0000712","EFO_0000612","EFO_0003763","HP_0004419","EFO_0001360","EFO_0005672","EFO_0004265"],"count":27},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for recurrent thrombophlebitis and has 9 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL839","canonicalSmiles":"CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2","inchiKey":"LWAFSWPYPHEXKX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARTEOLOL","yearOfFirstApproval":1988,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Carteolol","Cartrol","Ocupress"],"crossReferences":{"DailyMed":["carteolol%20hydrochloride"],"Wikipedia":["Carteolol"],"drugbank":["DB00521"],"chEBI":["3437"]},"childChemblIds":["CHEMBL1201002"],"count":2,"approvedIndications":["EFO_0000319","EFO_0000516"],"linkedTargets":{"rows":["ENSG00000169252","ENSG00000043591","ENSG00000188778"],"count":3},"linkedDiseases":{"rows":["EFO_0004190","EFO_0000319","EFO_0000516"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for glaucoma and cardiovascular disease."}
{"id":"CHEMBL841","canonicalSmiles":"CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1","inchiKey":"RDOIQAHITMMDAJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"LOPERAMIDE","yearOfFirstApproval":1976,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Imodium","Loperamide"],"crossReferences":{"DailyMed":["loperamide%20hydrochloride"],"PubChem":["104171181","11111380","11112740","11113732","124880549","124880551","124880553","144203731","170464852","26751916","26751917","50104594","50104595","90340730"],"Wikipedia":["Loperamide"],"drugbank":["DB00836"],"chEBI":["6532"]},"childChemblIds":["CHEMBL1707"],"count":12,"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","HP_0002014","HP_0000964","MONDO_0007254","EFO_0003929","EFO_0003843","EFO_0003060","HP_0004798","MONDO_0004565","EFO_0000311","EFO_0000305","EFO_0009130","EFO_0000512","EFO_0005611","EFO_0009523"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 12 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL90039","canonicalSmiles":"O=C(c1ccccc1)c1ccccc1","inchiKey":"RWCCWEUUXYIKHB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BENZOPHENONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Benzophenone"],"crossReferences":{"PubChem":["144207014","144209623","144210378","170465649","17389587","26752803","49816673"],"Wikipedia":["Benzophenone"],"drugbank":["DB01878"],"chEBI":["41308"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL94081","canonicalSmiles":"C=CCOc1ccc(CC(=O)O)cc1Cl","inchiKey":"ARHWPKZXBHOEEE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALCLOFENAC","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"],"classes":["Dermatological toxicity"," Vascular toxicity"],"year":1979},"tradeNames":["Mervan"],"synonyms":["Alclofenac","W 7320"],"crossReferences":{"PubChem":["144205279","29215481"],"Wikipedia":["Alclofenac"],"drugbank":["DB13167"],"chEBI":["31183"]},"count":1,"approvedIndications":["EFO_0005755"],"linkedTargets":{"rows":["ENSG00000095303"],"count":1},"linkedDiseases":{"rows":["EFO_0005755"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease. It was withdrawn in United Kingdom  in 1979 due to Dermatological toxicity and  Vascular toxicity."}
{"id":"CHEMBL95193","canonicalSmiles":"O=C(O)C1=C[C@@H](OP(=O)(O)O)[C@@H](O)[C@H](O)C1","inchiKey":"QYOJSKGCWNAKGW-PBXRRBTRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL95193","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04328"],"chEBI":["17052"]},"childChemblIds":["CHEMBL32352"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL953","canonicalSmiles":"CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1","inchiKey":"JRURYQJSLYLRLN-BJMVGYQFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENTACAPONE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Comtan","Comtess","Entacapone"],"synonyms":["Entacapone","OR-611"],"crossReferences":{"DailyMed":["entacapone"],"PubChem":["144205737","170464850","26757974"],"Wikipedia":["Entacapone"],"drugbank":["DB00494"],"chEBI":["4798"]},"count":6,"approvedIndications":["EFO_0002508"],"linkedTargets":{"rows":["ENSG00000093010"],"count":1},"linkedDiseases":{"rows":["EFO_0002610","EFO_0000474","EFO_0002508","Orphanet_44890","EFO_0004701","EFO_0001073"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for parkinson's disease and has 5 investigational indications."}
